评估自身免疫性脑炎的新患者报告结局量表:PROSE
研究开发了针对自身免疫性脑炎(AIE)的疾病特异性患者报告结局量表PROSE,基于202例抗LGI1、抗NMDAR或抗CASPR2脑炎患者的数据进行条目、因子和Rasch分析,最终形成40条目单维度量表,信效度良好,覆盖认知、行为、情绪与躯体健康、日常活动及参与。
要点
- PROSE为40条目单维度量表,覆盖认知、行为、情绪与躯体健康、日常活动及参与。
- 内部一致性(Cronbach's alpha=0.92)和重测信度(ICC=0.93)高。
- PROSE评分与诊断后时间相关(R=-0.32),并能前瞻性捕捉随时间改善。
核心结论
- PROSE是心理测量学稳健的疾病特异性患者报告结局评估工具,适用于自身免疫性脑炎。
研究设计与样本
- 基于202例抗LGI1(n=97)、抗NMDAR(n=85)和抗CASPR2(n=20)脑炎患者的数据进行分析。
- 对现有235个PROM条目进行内容效度评估并补充焦点小组条目,患者完成166条目的初步条目池。
- 通过条目分析、因子分析和Rasch分析精简条目池并创建PROSE,评估2周重测信度和与既定测量工具的收敛效度。
主要发现
- 分析支持40条目单维度等距量表用于患者感知的疾病严重程度。
- 内部一致性Cronbach's alpha=0.92(p<0.001),重测信度ICC=0.93(p<0.001,n=23)。
- PROSE评分与诊断后时间相关(R=-0.32,p=0.00018),并在前瞻性评估中捕捉到随时间改善(n=22)。
- PROSE与视觉模拟量表自评躯体健康(R=0.57)、情绪健康(R=0.57)和生活质量(R=0.57)呈合理至良好一致性(p<0.001)。
- PROSE与现有PROMs相关(ρ=0.42至ρ=0.81),与功能评分相关(mRS ρ=0.44,p<0.001;CASE ρ=0.40,p<0.001)。
关键数值与推荐
- PROSE包含40个条目,覆盖认知、行为、情绪和躯体健康、日常活动及参与。
- 人群诊断后中位时间3.5年(范围0.05-14年),其中41例诊断不足1年。
- 前瞻性重复评估52次,来自22例诊断不足24个月的患者。
临床怎么用
- PROSE可用于临床和试验中评估自身免疫性脑炎患者感知的疾病严重程度和结局。
- PROSE覆盖认知、行为、情绪与躯体健康、日常活动及参与,补充通用临床量表的不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Autoimmune encephalitis (AIE) has long-lasting effects. Generic clinical assessment-scales insufficiently capture disease-specific sequelae. Patient-reported outcome measures (PROMs) assess outcomes important to patients, ensuring relevance in the clinic and trials. We developed a disease-specific patient-reported outcome scale for encephalitis (PROSE). METHODS: Existing PROM-items (n = 235) were evaluated for content-validity and supplemented with focus-group-derived items. Patients with a history of anti-NMDAR, anti-LGI1, or anti-CASPR2 encephalitis completed the preliminary item pool (n = 166). To refine and reduce the item-pool and create the PROSE, we conducted item-, factor-, and Rasch-analyses. Test-retest reliability was assessed over 2 weeks and convergent-validity against established measures. RESULTS: The analysis included data from 202 patients with anti-LGI1 (n = 97), anti-NMDAR (n = 85), and anti-CASPR2 (n = 20) encephalitis, median 3.5 years from diagnosis (range = 0.05-14; n = 41 <1 year). Prospective, repeated assessments (n = 52) were available in 22 patients diagnosed <24 months prior. Analyses supported the viability of a 40-item unidimensional interval scale for patient-perceived disease-severity: the PROSE. The person-separation (Cronbach's alpha = 0.92, p < 0.001) and test-retest reliability (intra-class correlation-coefficient = 0.93, p < 0.001, n = 23) were high. PROSE covers cognition, behavior, emotional and physical wellbeing, daily activities, and participation. PROSE scores were normally distributed and informative across subtypes and demographic groups, correlated with time-since-diagnosis (R = -0.32, p = 0.00018) and captured improvement over time prospectively (n = 22). They showed reasonable-to-good agreement with self-reported physical and emotional wellbeing (R = 0.57 and 0.55, p < 0.001) and quality of life (R = 0.57, p < 0.001) on Visual Analogue Scales, to existing PROMs (ρ = 0.42 to ρ = 0.81) and functional scores (mRS ρ = 0.44, p < 0.001, CASE ρ = 0.40, p < 0.001), with strongest correlations to aggregate constructs. INTERPRETATION: PROSE is a psychometrically robust, disease-specific patient-reported outcome assessment-tool for encephalitis. ANN NEUROL 2026;100:511-524.
引用
- Brenner J, Crijnen YS, Kulderij I, et al. A new Patient-Reported Outcome Scale to assess autoimmune Encephalitis: PROSE. Ann Neurol. 2026. PMID: 42410660. doi:10.1002/ana.78287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。